GlassScriptPhysician profile
Angela Winstead
NPI 1033515267
$4,104.33
in general payments reported to CMS, 2019-2025
31 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $503 · 2022: $622 · 2023: $571 · 2024: $658 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $920.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $366.23 | 2023-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $301.47 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $278.76 | 2024-2025 | |
| Dexcom, INC. | $234.79 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbvie INC. | $233.83 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $212.80 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Inspire Medical Systems, INC. | $187.56 | 2025 | Inspire |
| Abbott Laboratories | $182.13 | 2022-2025 | Freestyle Libre |
| Lilly USA, LLC | $167.33 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $128.69 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $115.56 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $97.62 | 2023-2024 | Xarelto |
| Shield Therapeutics INC | $92.79 | 2024 | |
| Pfizer INC. | $70.25 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $68.81 | 2025 | Keveyis, Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $60.83 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.16 | 2022-2023 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $57.77 | 2022-2023 | Austedo, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.95 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $34.94 | 2025 | Veozah |
| Halozyme INC | $31.67 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $24.61 | 2025 | Zoryve |
| Insmed, INC. | $23.22 | 2025 | Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $20.54 | 2022 | |
| Boston Scientific Corporation | $15.80 | 2025 | Varithena Administration Pack |
| Axsome Therapeutics, INC. | $15.09 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $14.68 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $13.72 | 2023 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $13.11 | 2024 | |
| Genentech USA, INC. | $8.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Winstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.